Top Page
PureTech Health
(LSE:PRTC)
PureTech Health (PRTC) vs. iShares MSCI United Kingdom ETF (EWC)
PureTech Health Business Overview & Revenue Model
PureTech Health Earnings Call Summary
PureTech Health Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.88M | 4.32M | 750.00K | 2.09M | 9.98M | 8.34M |
| Gross Profit | 19.91M | 4.32M | -92.91M | -136.81M | -100.49M | 8.34M |
| EBITDA | 55.73M | 37.38M | -17.68M | -79.94M | -46.95M | -115.58M |
| Net Income | 50.68M | 53.51M | -65.70M | -50.35M | -60.56M | 5.99M |
Balance Sheet | ||||||
| Total Assets | 553.24M | 602.63M | 693.97M | 702.65M | 946.01M | 989.99M |
| Cash, Cash Equivalents and Short-Term Investments | 321.55M | 367.31M | 327.14M | 350.10M | 465.71M | 403.88M |
| Total Debt | 20.92M | 22.36M | 25.34M | 46.87M | 52.75M | 76.62M |
| Total Liabilities | 184.22M | 194.70M | 235.74M | 155.06M | 361.86M | 336.45M |
| Stockholders Equity | 375.98M | 414.71M | 464.07M | 542.22M | 593.51M | 669.75M |
Cash Flow | ||||||
| Free Cash Flow | -100.31M | -134.38M | -106.16M | -180.97M | -163.94M | -137.25M |
| Operating Cash Flow | -100.30M | -134.37M | -105.92M | -178.79M | -158.27M | -131.83M |
| Investing Cash Flow | 34.05M | 240.89M | 68.99M | -107.22M | 197.38M | 364.48M |
| Financing Cash Flow | 18.37M | -16.96M | 78.14M | -29.83M | 22.73M | 38.87M |
PureTech Health Technical Analysis
PureTech Health Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | £107.11M | 14.11 | 64.40% | 6.75% | -3.61% | -6.38% | |
| ― | £319.02M | 9.24 | 15.04% | ― | 1231.50% | ― | |
| ― | £789.76M | ― | -74.64% | ― | 55.44% | 75.77% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | £1.36B | ― | -26.01% | ― | 22.03% | 20.01% | |
| ― | £102.22M | -7.46 | ― | ― | ― | -94.12% | |
| ― | £112.27M | -7.30 | -209.34% | ― | 198.49% | -26.66% |
PureTech Health Corporate Events
PureTech Health has announced new analyses from its Phase 2b ELEVATE IPF trial, demonstrating the consistent safety and efficacy of deupirfenidone in treating idiopathic pulmonary fibrosis (IPF) among older patients, a group historically undertreated due to tolerability issues. The findings, presented at the CHEST 2025 Annual Meeting, suggest that deupirfenidone could address a significant treatment gap for older IPF patients, potentially offering a new standard of care and improving outcomes for this vulnerable population.
The most recent analyst rating on (GB:PRTC) stock is a Hold with a £135.00 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
PureTech Health has announced promising new data from its Phase 2b ELEVATE IPF trial for deupirfenidone (LYT-100), a potential new standard of care for idiopathic pulmonary fibrosis (IPF). The data, presented at the 2025 European Respiratory Society Congress, showed that patients switching from placebo or pirfenidone to deupirfenidone experienced stabilization of lung function with favorable tolerability, reinforcing the drug’s potential to address unmet needs in IPF treatment. The company is engaging with regulators to finalize the Phase 3 trial design, with updates expected in Q4 2025.
The most recent analyst rating on (GB:PRTC) stock is a Hold with a £130.00 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
PureTech Health announced that key members of its management team, including the Interim CEO and several Non-Executive Directors, have purchased shares in the company. This transaction, conducted on the London Stock Exchange, signifies confidence in the company’s future prospects and may positively influence stakeholder sentiment.
The most recent analyst rating on (GB:PRTC) stock is a Hold with a £130.00 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
Seaport Therapeutics has initiated a Phase 1 clinical trial for GlyphAgo, an oral prodrug of agomelatine, aimed at treating generalized anxiety disorder (GAD). GlyphAgo is designed to improve drug absorption and reduce liver-related side effects, potentially redefining GAD treatment by achieving therapeutic benefits at lower doses without the need for frequent liver monitoring.
The most recent analyst rating on (GB:PRTC) stock is a Hold with a £130.00 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
PureTech Health announced its total voting rights and share capital as of August 31, 2025, with 257,927,489 ordinary shares issued and 16,243,451 held in treasury, resulting in 241,684,038 total voting rights. This disclosure is significant for shareholders who need to assess their interests under the FCA’s rules, impacting their investment decisions and the company’s transparency in the market.
The most recent analyst rating on (GB:PRTC) stock is a Hold with a £130.00 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
The recent earnings call for PureTech Health painted a picture of cautious optimism. The company showcased its strong financial health and promising advancements in its core programs, yet the recent management changes and ongoing efforts to secure external funding introduced some uncertainties. Overall, the strategic initiatives and financial position of PureTech suggest a cautiously optimistic outlook.
PureTech Health has reported significant progress in its diversified portfolio, with multiple programs moving towards late-stage development. The company has launched Celea Therapeutics and maintained a strong financial position, ensuring operational flexibility until 2028. Strategic priorities include advancing promising programs, strengthening UK capital market engagement, and disciplined capital allocation. The company is set to initiate a Phase 3 trial for deupirfenidone in 2026 and expects reduced operational expenses as responsibilities transition to external entities. Leadership changes and a search for new directors aim to enhance shareholder value.
The most recent analyst rating on (GB:PRTC) stock is a Hold with a £141.00 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
PureTech Health has showcased its development strategy at the 2025 IPF Summit, highlighting the Phase 2b ELEVATE IPF trial data for deupirfenidone, which is set to advance into Phase 3 trials. The company emphasizes a holistic approach to development, incorporating patient insights and sophisticated trial designs to potentially establish deupirfenidone as a new standard of care in IPF, with its newly launched entity, Celea Therapeutics, leading the effort.
The most recent analyst rating on (GB:PRTC) stock is a Hold with a £142.00 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
PureTech Health announced that it will release its half-yearly financial results for the first half of 2025 on August 28, 2025. The announcement will be accompanied by a presentation and conference call for analysts and shareholders, which indicates the company’s commitment to transparency and engagement with stakeholders. This release is significant for stakeholders as it provides insights into the company’s financial health and strategic direction.
The most recent analyst rating on (GB:PRTC) stock is a Buy with a £4.55 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
Vedanta Biosciences, a PureTech Founded Entity, announced that its Phase 2 study of VE202 for ulcerative colitis did not meet its primary endpoint, though the treatment was well tolerated. Despite this setback, Vedanta will focus on its Phase 3 study of VE303 for preventing recurrent Clostridioides difficile infection, which has shown promising Phase 2 results. This strategic shift underscores Vedanta’s commitment to addressing unmet medical needs in gastrointestinal health, with potential implications for stakeholders as the company advances its pipeline.
The most recent analyst rating on (GB:PRTC) stock is a Buy with a £4.55 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
PureTech Health has launched Celea Therapeutics, a new entity focused on transforming the treatment of respiratory diseases, with former Teva North America CEO Sven Dethlefs leading the initiative. Celea’s lead program, deupirfenidone (LYT-100), is a Phase 3-ready candidate aimed at treating idiopathic pulmonary fibrosis (IPF), a severe lung disease. The launch underscores PureTech’s commitment to advancing innovative therapies through focused structures, and the appointment of Dr. Dethlefs, with his extensive experience, is expected to drive the program’s success. The development of deupirfenidone, which has shown promising Phase 2b results, represents a significant opportunity in the IPF market, which is currently underserved by existing treatments.
The most recent analyst rating on (GB:PRTC) stock is a Buy with a £4.55 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.
PureTech Health announced its total voting rights and share capital as of July 31, 2025, with 241,316,327 voting rights available. This information is crucial for shareholders to determine their notification obligations under the FCA’s rules, reflecting PureTech’s commitment to transparency and regulatory compliance.
The most recent analyst rating on (GB:PRTC) stock is a Buy with a £455.00 price target. To see the full list of analyst forecasts on PureTech Health stock, see the GB:PRTC Stock Forecast page.